# A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

> **NCT00162318** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 30 (—)

## Conditions studied

- Non-Small-Cell Lung Carcinoma

## Interventions

- **DRUG:** Cetuximab + Gefitinib

## Key facts

- **NCT ID:** NCT00162318
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2006-04
- **Final completion:** 2006-04
- **Target enrollment:** 30 (—)
- **Last updated:** 2015-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00162318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00162318, "A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00162318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*